药师管理糖尿病门诊对高危2型糖尿病患者疗效的随机对照II期研究方案
本研究为开放标签、随机对照、平行分组II期试验,在密歇根州Beaumont医院门诊开展,纳入18岁以上、确诊2型糖尿病且血红蛋白A1c≥9%的患者,随机分为标准治疗组与标准治疗加药师管理糖尿病门诊组,主要结局为6个月和12个月时血红蛋白A1c的变化,旨在评估药师管理门诊对糖尿病核心指标、生活质量、安全性和费用的影响。
要点
- 纳入标准为年龄>18岁、2型糖尿病、血红蛋白A1c≥9%且近3个月未接受药师管理门诊治疗。
- 主要结局为6个月和12个月时血红蛋白A1c相对基线的变化。
- 次要结局包括糖尿病核心指标、生活质量、安全性和费用影响。
核心结论
- 研究假设药师管理糖尿病门诊将对糖尿病核心指标产生显著正面影响,以更低费用提供更高质量照护。
研究设计与样本
- 开放标签、随机对照、平行分组II期试验,在Beaumont医院Royal Oak院区门诊开展。
- 纳入年龄>18岁、确诊2型糖尿病且血红蛋白A1c≥9%、已建立初级保健住院医师且近3个月未就诊药师管理门诊的患者。
- 患者随机分配至标准治疗组或标准治疗加药师管理糖尿病门诊组。
关键数值与推荐
- 主要结局为6个月和12个月时血红蛋白A1c的变化。
- 次要结局包括所有糖尿病核心指标、患者生活质量、伤害及干预相关费用影响。
临床怎么用
- 若干预结果与既往回顾性分析一致,可为未来多中心随机对照试验提供框架。
- 结果可能影响未来糖尿病指南,促使将药师管理糖尿病门诊纳入标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Millions of Americans are currently living with diabetes and approximately 1.5 million cases are being diagnosed each year. Diabetes is now the seventh leading cause of death in the United States. In addition, the economic burden of the disease has resulted in billions of dollars in health care costs. In spite of these investments, the United States lags behind other developed countries on diabetes life expectancy and disease-related deaths. The purpose of this study is to assess the impact of a pharmacist-managed diabetes clinic (PMDC) model on diabetes core measures. Our hypothesis is that a PMDC would have a significant positive impact on the diabetes measures and will result in higher-quality care at a lower price. METHODS: This study is a randomized, open-label, controlled, parallel-group trial which will be conducted in the outpatient clinic at Beaumont Hospital, Royal Oak, Michigan. Patients will be randomly assigned to one of two groups: standard of care (SOC) or standard of care plus PMDC (SOC + PMDC). Included in the study will be patients older than 18 years of age with a diagnosis of type 2 diabetes mellitus and a hemoglobin A1c ≥ 9%, who are established with a primary care resident and who have not been seen in the PMDC within the last 3 months. The primary outcome is the change in hemoglobin A1c, measured at 6 and 12 months. Secondary outcomes include the impact on all diabetes core measures, patient quality of life, harms, and cost impact related to the intervention. DISCUSSION: If the results of this trial are consistent with the previous retrospective analysis that a pharmacy clinic has a significant impact in controlling hemoglobin A1c levels as well as other diabetes core measures to improve clinical outcomes, it will constitute a scaffold for a future multicenter, randomized controlled trial. In addition, these results may influence future diabetes guidelines, leading to the inclusion of a PMDC as the standard of care. The impact of these results on the economic burden, life expectancy, and diabetes-related deaths are needed and have yet to be studied. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03377127 . Protocol version: registered on 10 February 2018; version #1.
引用
- Halalau A, Shelden D, Keeney S, et al. Pharm-MD; an open-label, randomized controlled, phase II study to evaluate the efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients - study protocol for a randomized controlled trial. Trials. 2018. PMID: 30143033. doi:10.1186/s13063-018-2836-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。